O2 RegenTech, a medical technology company focused on wound care solutions, has been awarded a $225,000 National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant to conduct research and development on its oxygenating wound dressing that enhances chronic wound healing. Additionally, the company received a $225,000 National Institutes of Health (NIH) Small Business Technology Transfer (STTR) grant and $150,000 from the Ohio Third Frontier (OTF) Technology Validation and Startup Fund (TVSF).
The three most important factors in wound healing are oxygen, moisture, and protection from bacteria to prevent infections. Currently, there are no wound treatments available that offer all three components at once, requiring patients to use a combination of different bandages, dressings, ointments, and other treatments. O2 RegenTech aims to make wound care simpler with its proprietary product, OXAID™, a treatment that provides all three important components to promote wound healing in one easy-to-use dressing.
“O2 RegenTech is extremely excited to receive the support of the NSF, the NIH, and the OTF,” said Dr. Andreas Inmann, President & CEO of O2 RegenTech. “This funding validates our approach and will be instrumental in moving our technology closer to regulatory submission and commercialization.”